• Bone Biologics

  Led · Equity · Nov 2014

  Bone Biologics develops and markets orthobiologic products focused on spine fusion, built on a proprietary platform technology called NELL-1, a recombinant human protein growth factor essential for normal bone development. Its lead product is a NELL-1-based bone graft substitute for spine fusion, designed to provide targeted regulation over bone regeneration in the presence of osteogenic cells. The company is led by CEO and President Stephen R. La Neve and COO Jeff Frelick. Bone Biologics completed a $1.4M funding round as the first round of a previously announced private placement. Proceeds will be used for working capital, protein development, laboratory and testing equipment, regulatory and clinical expenses, efforts to extend the patent life of NELL-1, and other activities directly related to growing the business and R&D. The company trades on the OTC under the ticker BBLG and is based in Burlington, MA. Bone Biologics develops a proprietary recombinant human protein called Nell-1 (UCB-1) for bone regenerative medicine, with a focus on spinal fusion. Nell-1 was developed in partnership with the University of California, Los Angeles (UCLA) and the Musculoskeletal Transplant Foundation (MTF). In large animal studies, Nell-1 exhibited none of the side effects associated with other bone growth factors, including ectopic bone growth, extraneous bone growth, or cyst formation. The company is led by CEO Michael Schuler and is based in Edison, New Jersey. Bone Biologics completed a $2M funding round and intends to use the funds to continue process development and to advance manufacturing of Nell-1 in preparation for human clinical trials and regulatory submission. Bone Biologics develops a patented recombinant human protein known as UCB-1 (Nell-1) for bone regenerative medicine, particularly for patients undergoing spinal fusion. The protein was developed in partnership with UCLA and the Musculoskeletal Transplant Foundation (MTF) as a more specific alternative to existing bone growth factors. The company is led by CEO Michael Schuler and is based in Los Angeles. Bone Biologics completed a $5M funding round to support near-term operational work. The firm intends to use the proceeds to begin manufacturing Nell-1 in preparation for human clinical trials to validate the technology. No operating metrics or prior financings were disclosed in the article. Bone Biologics focuses on orthobiologics and has developed a platform centered on UCB-1, a proprietary skeletal-specific growth factor that targets cells with an activated master switch to become bone or cartilage. The platform is intended to improve outcomes across spinal, orthopedic, plastic reconstruction, neurosurgery, interventional radiology and sports medicine procedures. UCB-1 and the platform will be subject to FDA review and clinical trials and are not currently approved for use in humans. Financially, the company received an undisclosed investment from the Musculoskeletal Transplant Foundation (MTF), which now owns a majority stake, and MTF also provided a line of credit. That financing and credit have funded continuing operations and allowed Bone Biologics to progress from research through development of UCB-1. Mark Spilker, PhD, MTF’s Vice President of Research & Development, has been elected to the Bone Biologics board of directors.

No current team members are available.